Answering Warnies question, my understanding is when drug companies merge, they often rationalise the research programs of drugs they are developing to prioritise the ones they see have bigger potential in treatment segments, plus save $$. I believe this was the case with Bisantrene.
Mcap $6.7 M / Big EFFECTIVE Cancer Drug in P3 (MKT Size ~$500M+) =20+BAGGER, page-28
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $282.0M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
